An Atypical Presentation of Rheumatoid Arthritis as an Asymmetrical Arthropathy

Marc Wong 1, Chong Jia Loon 1, C. Rajasoorya 1

1. Internal Medicine, Sengkang General Hospital, Singapore, SGP

Corresponding author: C. Rajasoorya, c.rajasoorya@singhealth.com.sg

Abstract

We report a rare entity of distinctly asymmetrical rheumatoid arthritis (RA) in a 71-year-old Chinese lady with a history of cervical radiculopathy secondary to trauma sustained during childhood. The joints on the side of the paresis were spared from severe clinical and radiological manifestations of RA. We review the plausible mechanisms that could explain the link between neurological impairment and rheumatoid joint involvement.

Introduction

Rheumatoid arthritis (RA) is a chronic progressive inflammatory disease with the hallmark of this disease characterized by joint inflammation manifested by joint swelling, immune cell infiltrations, neovascularization, and synovial hyperplasia. Progression of this disease leads to bone erosion and joint destruction culminating in the classical presentation of symmetrical deforming polyarthropathy. In the case of our patient, asymmetrical RA changes were seen, attenuated in severity over her left hand that was concomitantly affected by long-standing paresis from lower cervical radiculopathy secondary to trauma sustained during childhood.

Case Presentation

A 71-year-old Chinese lady was seen for progressive bilateral lower limb weakness and prolonged right-hand pain. The lower limb weakness was predominantly proximal, worsened over three months, and had resulted in recurrent falls.

The pain in her right hand was described as intermittent, worse over the wrist and small joints with early morning stiffness lasting a few hours. She sought medical attention over the preceding one year and had been treated with multiple courses of prednisolone. She denied any symptoms of numbness and paresthesia of her extremities. Comparatively, her left hand was unaffected by joint pain or swelling. It was notably weaker and less functional since childhood after sustaining trauma.

She had no other associated rheumatologic manifestations such as alopecia, rash, photosensitivity, oral ulcer, dry mouth, or dry eyes. Her past medical history was significant for the lumbar vertebral body, L1 burst fracture requiring T11 to L3 pedicle screw construct.

Physical examination revealed asymmetrical bilateral upper limb polyarthropathy and proximal myopathy. Over her right hand, there was bony swelling over the wrist, ulnar deviation, and Z thumb deformity. There was swelling over the proximal interphalangeal joints (PIP) with tenderness over the second PIP (Figures 1, 2) with notable sparing of her distal interphalangeal (DIP) joints. She was not able to flex or extend her right wrist and was unable to make a fist with her right hand.
FIGURE 1: Bilateral hands with right hand showing ulnar deviation and Z thumb
Over at her left hand, although there was an ulnar deviation, flexion and extension of the wrist were maintained up to 50 and 70 degrees, respectively (Figure 3). There was Boutonniere deformity of the left third digit with an examination of the other joints being unremarkable. She maintained the ability to make a fist with her left hand.
Investigations revealed elevated levels of rheumatoid factor (55 U/mL, normal range < 10.3 U/mL), anti-cyclic citrullinated peptide (12 U/mL, normal range < 5 U/mL), erythrocytes sedimentation rate (86 mm/hr, normal range 3-20 mm/hr), and C-reactive protein (65.6 mg/L, normal range 0.2-9.1 mg/L). A short Synacthen test revealed a sub-optimal response with basal levels of cortisol of 184 nmol/L rising to a maximal of 442 nmol/L at 60 mins after stimulation. X-ray of hands showed advanced degeneration of the right wrist with the collapse of the carpal bones, Boutonniere deformity of the right thumb, and bilateral juxta-articular osteopenia (Figures 4, 5). Nerve conduction study and electromyography studies reveal left lower cervical radiculopathy.
The patient’s clinical presentation is compatible with seropositive RA with a European League Against Rheumatism (EULAR) score of 7 [1]. With prolonged use of oral steroids for arthralgia, she has now developed associated complications of osteoporosis-related compression fractures, proximal myopathy, and adrenal insufficiency. She was gradually tapered off steroids and had her function optimized through rehabilitation.

**Discussion**

The classical presentation of rheumatoid hands is symmetrical deforming polyarthritis. Since one of the earliest descriptions by Thompson and Bywaters in 1962 [2] of a patient with attenuated severity of RA in the affected limb after a stroke, there have been sporadic reports of such an entity as well as many

**FIGURE 4: X-ray of the hands, PA view**

Advanced degeneration of the right wrist with the collapse of the carpal bones with boutonniere deformity of the right thumb while the left hand was unremarkable - save for osteopenia

**FIGURE 5: X-ray of the hands, ball catcher’s view**

The patient’s clinical presentation is compatible with seropositive RA with a European League Against Rheumatism (EULAR) score of 7 [1]. With prolonged use of oral steroids for arthralgia, she has now developed associated complications of osteoporosis-related compression fractures, proximal myopathy, and adrenal insufficiency. She was gradually tapered off steroids and had her function optimized through rehabilitation.

**Discussion**

The classical presentation of rheumatoid hands is symmetrical deforming polyarthritis. Since one of the earliest descriptions by Thompson and Bywaters in 1962 [2] of a patient with attenuated severity of RA in the affected limb after a stroke, there have been sporadic reports of such an entity as well as many
impairment should not be missed in a patient presenting with asymmetrical arthropathy in a patient who its severity when there is a coexistent neurological impairment on the ipsilateral limb. Second, neurological first is the need to consider the possibility of a rare presentation of an asymmetrical RA with attenuation of edema-related complications. Two important learning points can be gleaned from this case illustration, the likelihood of infections, a decrease in vascular permeability brought on by paralysis may help to minimize downregulation of genes with a role in vascular permeability, conferring resistance to the development of RA.

The clinical manifestations of RA are attenuated in severity in the presence of paresis. While initially it was attributed to enforced immobility, increasing evidence points toward denervation leading to the downregulation of genes with a role in vascular permeability, conferring resistance to the development of arthritis. As paralysis can bring on venous and lymphatic stasis which may result in edema and increased likelihood of infections, a decrease in vascular permeability brought on by paralysis may help to minimize edema-related complications. Two important learning points can be gleaned from this case illustration, the first is the need to consider the possibility of a rare presentation of an asymmetrical RA with attenuation of its severity when there is a coexistent neurological impairment on the ipsilateral limb. Second, neurological impairment should not be missed in a patient presenting with asymmetrical arthropathy in a patient who has neurological impairment.

Conclusions

The clinical manifestations of RA are attenuated in severity in the presence of paresis. While initially it was attributed to enforced immobility, increasing evidence points toward denervation leading to the downregulation of genes with a role in vascular permeability, conferring resistance to the development of arthritis. As paralysis can bring on venous and lymphatic stasis which may result in edema and increased likelihood of infections, a decrease in vascular permeability brought on by paralysis may help to minimize edema-related complications. Two important learning points can be gleaned from this case illustration, the first is the need to consider the possibility of a rare presentation of an asymmetrical RA with attenuation of its severity when there is a coexistent neurological impairment on the ipsilateral limb. Second, neurological impairment should not be missed in a patient presenting with asymmetrical arthropathy in a patient who has neurological impairment.

In 2014, Stangenberg et al. [10] used mice models and successfully demonstrated reproducible changes at the transcriptional level affected by denervation. In that study, they utilized the K/BxN T-cell receptor transgenic mouse model which allows an inflammatory phenotype to be induced by serum transfer, making it an ideal model to study RA [11,12].

These experimental K/BxN mice underwent surgical unilateral transaction of the sciatic and femoral nerve resulting in hemiplegia. For controls, a paired sham operation was performed on the contralateral hind limb. K/BxN serum was injected into the intraperitoneal space, inducing an inflammatory arthritis phenotype to facilitate the study of inflammation in the presence of denervation. This study demonstrated decreased inflammation in the joint spaces of the paws of mice in the presence of denervation.

Comparing the transcriptomes obtained from endothelial cells obtained from denervated paws and their controls revealed the downregulation of genes involved in the regulation of vascular permeability [10]. The downstream effects of this are postulated to be regulated through an effector molecule Junctional Adhesion Molecule B (JAM-B), which has previously been shown to have roles in the development of arthritis in mice models and endothelial cell stability [13].

JAM-B has a human homolog, JAM-C, known to be upregulated in the endothelial cells of the synovium affected by RA [13,14]. It facilitates leukocyte adhesion and transmigration to joint spaces as well as adhesion to synovial fibroblasts [15]. The cleaved product of JAM-C, soluble JAM-C is shed from endothelial surfaces in response to inflammation and functions as a pro-angiogenic mediator [15]. Neutralizing antibodies targeted against JAM-C was also shown to delay the onset as well as to decrease the severity of inflammation of arthritis in mice models [16].

Taken together, it is postulated that innervation by the nervous system has a role in regulating the microvascular environment of inflammatory arthritis. It provides a signal required to maintain levels of effector molecules such as JAM-C, which in turn increases the vascular permeability of the microenvironment. When this signal is lost through denervation, it results in the alteration of the gene expression profile of endothelial cells in the synovium resulting in decreased vascular permeability. The decrease in vascular permeability could have then contributed to a reduction in the access to arthritogenic cells and molecules, resulting in a decreased inflammatory phenotype [10].

Currently, there is much work that remains to fully elucidate how the nervous system intrinsically regulates the immune system and its downstream effects other than to alter vascular permeability.
otherwise has typical RA.

**Additional Information**

**Disclosures**

- **Human subjects:** Consent was obtained or waived by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

**References**

1. Aletaha D, Neogi T, Silman AJ, et al.: 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010, 62:2569-81. 10.1002/art.27584
2. Thompson M, Bywaters EG: Unilateral rheumatoid arthritis following hemiplegia. Ann Rheum Dis. 1962, 21:570-7. 10.1136/ard.21.4.570
3. Glick EN: Asymmetrical rheumatoid arthritis after poliomyelitis. Br Med J. 1967, 5:26-8. 10.1136/bmj.3.5556.26
4. Matsuno H, Tsuji H, Nakazawa F: Asymmetrical manifestation of rheumatoid arthritis in poliomyelitis. Jpn J Rheumatol. 1998, 52:141-5.
5. Smith RD, Polley HF: Rest therapy for rheumatoid arthritis. Mayo Clinic Proc. 1978, 53:122-9.
6. Smith RD: Effect of hemiparesis on rheumatoid arthritis. Arthritis Rheum. 1979, 22:1419-20. 10.1002/art.1780221225
7. Patrick M, Doherty M, Dieppe P: Unilateral exacerbation of rheumatoid arthritis by hemiparesis. Rheumatology. 1984, 25:107-9.
8. Decaris E, Guingamp C, Chat M, et al.: Evidence for neurogenic transmission inducing degenerative cartilage damage distant from local inflammation. Arthritis Rheumatol. 1999, 42:1951-60. 10.1002/1529-0131(199909)42:9<1951::AID-ANR22>3.0.CO;2-D
9. Keyszer G, Langer T, Kornhuber M, et al.: Neurovascular mechanisms as a possible cause of remission of rheumatoid arthritis in hemiparetic limbs. Ann Rheum Dis. 2004, 63:1349-51. 10.1136/ard.2003.016410
10. Stangenberg L, Burzyn D, Binstadt BA, et al.: Denervation protects limbs from inflammatory arthritis via an impact on the microvasculature. Proc Natl Acad Sci U S A. 2014, 111:11419-24. 10.1073/pnas.1410854111
11. Kouskoff V, Korganow AS, Duchatelle V, et al.: Organ-specific disease provoked by systemic autoimmunity. Cell. 1996, 87:811-22.
12. Monach PA, Mathis D, Benoist C: The K/BxN arthritis model. Curr Protoc Immunol. 2008, Chapter 15:Unit 15.22. 10.1002/0471142755.im1522s81
13. Weber C, Fraemohs L, Dejana E: The role of junctional adhesion molecules in vascular inflammation. Nature Rev Immunol. 2007, 7:467-77.
14. Rabquer BJ, Pakozdi A, Michel JE, Gujar BS, Haines GK 3rd, Imhof BA, Koch AE: Junctional adhesion molecule C mediates leukocyte adhesion to rheumatoid arthritis synovium. Arthritis Rheum. 2008, 58:3020-9. 10.1002/art.23867
15. Rabquer BJ, Amin MA, Teegala N, et al.: Junctional adhesion molecule-C is a soluble mediator of angiogenesis. J Immunol. 2010, 185:1777-85.
16. Palmer G, Busso N, Aurrand-Lions M, et al.: Expression and function of junctional adhesion molecule-C in human and experimental arthritis. Arthritis Res Ther. 2007, 9:R65. 10.1186/ar2223